Rho-Associated Kinases

Aerie Pharmaceuticals has submitted a marketing authorization application for Roclanda to the European Medicines Agency, according to a press release.

A pivotal trial designed to assess KD025 for patients with pretreated chronic graft-versus-host disease met its primary endpoint of overall response rate, according to results from a planned interim analysis.

A Japanese phase 2 clinical study of netarsudil ophthalmic solution showed a significant reduction in mean intraocular pressure compared with placebo, Aerie Pharmaceuticals announced in a press release.

PARIS — For some patients, the use of a topical Rho kinase inhibitor following a Descemet’s stripping only procedure for Fuchs’ dystrophy “can be life-changing,” Kathryn Colby, MD, PhD, said at EuCornea 2019.